Announced Tue, 26 May · 17:45 IST

Financial results for the year ended March 31, 2026

Pat Growth 25pctEbitda Margin ExpansionNegative Operating CashflowResults View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+11.6%1-day move

₹97.65

prior close

₹103.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.0+9.7+9.7+9.7+11.6+4.5-2.7-2.7-3.7——+1.4+8.0—

Up moveDown movePending

AI summary

EP Biocomposites reported strong full-year results with revenue growing 13.6% to Rs. 1,363.98 lakh from Rs. 1,200.62 lakh. PAT surged 41.5% to Rs. 145.83 lakh vs Rs. 103.08 lakh in the prior year. Basic EPS stood at Rs. 8.67 versus Rs. 6.13. Operating cash flow turned positive at Rs. 198.94 lakh after being negative at Rs. 48.98 lakh last year. Total assets grew to Rs. 1,873.14 lakh from Rs. 1,662.66 lakh. The company completed its IPO raising Rs. 635 lakh and fully deployed the net proceeds of Rs. 580.04 lakh as per the prospectus. Long-term borrowings reduced from Rs. 245.15 lakh to Rs. 186.96 lakh. The auditor issued an unqualified opinion with no going concern or other adverse notes.

Likely market impact

Strong earnings growth with improved profitability margins and positive cash generation signals healthy operational performance. The debt reduction and IPO deployment enhance the company's balance sheet strength, which is positive for shareholders.